Discover our main news for the first half of 2022!

Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!

Explicyte’s partnership with Domain Therapeutics has been running since this year!

Explicyte is very proud to have granted Domain Therapeutics the exclusivity on data related to GPCR implicated in immunoresistance, in order to develop innovative, first-in class cancer therapies.

Learn more
New cutting-edge platforms for biomarker translational research

Thanks to its certified partnerships, Explicyte now offers:

  • Spatial transcriptomics to deal with the tumor biology complexity & heterogeneity
  • High proteomic analysis capabilities for comprehensive protein biomarker discovery


Check out our capabilities

Discover our newest featured publications

Led in collaborations with renowned researchers, many of our works underlining Explicyte’s expertise and strengths were recently published in peer-reviewed journals.


Read the papers


Leave a Reply

Your email address will not be published.

This field is required.

You may use these <abbr title="HyperText Markup Language">html</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

This field is required.

WordPress Lightbox